Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?
Arnaud
Laurent
L
Sene
Damien
D
Costedoat-Chalumeau
Nathalie
N
Cacoub
Patrice
P
Chapelon-Abric
Catherine
C
Piette
Jean-Charles
JC
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000935:Antifungal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D003453:Cryptococcosis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology*; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000276:immunology; D004359:Drug Therapy, Combination; D006321:Heart / Q000382:microbiology; D006331:Heart Diseases / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D055414:Myocardial Perfusion Imaging; D009206:Myocardium / Q000473:pathology; D012507:Sarcoidosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab